Biomarkers as an Emerging Growth Area in Denmark
The aim of “Biomarkers as an emerging growth area" is to create better opportunities in Denmark for prevention of diseases, diagnosis and treatment by facilitating cross disciplinary collaboration in a partnership model of ICT, research and clinical development having focus on patient centricity, on the identification, validation and use of biomarkers.
In parallel, we explore how to build a "Danish infrastructure model" on biomarker research and development in a public-private partnership model among all stakeholders in order to strengthen biomarker innovation i Denmark.
International Conference on Perspectives in Precision Medicine
National and international delegates from companies, research institutions and the Health Sector will meet, share knowledge, form new projects and relationsships, identify project funding and learn about Precision Medicine seen from new and exciting perspectives. Conference web page: biopeople.eu/conference-perspectives-in-precision-medicine/
Accelerate your growth; Options for funding and coaching
Biomarker commercialization project approved
The goal of the project is to increase the commercial potential of biomarker discoveries in the Baltic Sea RegionIdeklinikken at Aalborg University Hospital, the University of Turku, Finland, The University of Vilnius, Lithuania, and the 6 innovation clusters Biopeople (Denmark), BioCon Valley (Germany), Turku Science Park (Finland), Tartu Biotechnology Park (Estonia), Wroclaw Technology Park (Poland) and ScanBalt covering the Baltic Sea Region earlier this year applied for an interregional project related to the commercialization of biomarkers (BiC). The project will create and stimulate synergies between industry, cluster organizations and research institutions across the Baltic Sea Region.Read more about Biomarker commercialization project approved.
The European Patients' Academy on Therapeutic Innovation (EUPATI) has the objective to produce reliable and objective educational material to patients on the research and development process of medicines in order to introduce a paradigm shift towards having patients much more actively engaged in medicines R&D.
EUPATI will provide scientifically reliable, objective, comprehensive information to patients and patient organization across Europe different languages (including Danish) on the research and development process of medicines from early start to market of new medicines.
The aim is to increase the capacity of patients to be effective advocates and advisors, e.g., in clinical trials, with regulatory authorities and in ethics committees and to make a visible difference, showing ways that can have a more meaningful involvement in areas like drug discovery, the safety of medicines and access to treatments.
EUPATI is a highly collaborative public private partnership project lead by patients consisting of 30 partners including patient advocacy groups, academic institutions, not-for-profit organisations and pharmaceutical companies.
Biopeople is consortia partner in EUPATI and plays a pivotal role in producing scientific reliable, objective and comprehensive educational material to patients across Europe.